G. Wichert

Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas.

F. Lordick, Ö. Türeci, U. Şahin, 2013 .

A phase I/II study of oxaliplatin and paclitaxel in patients with non-resectable cancer of the oesophagus and adenocarcinoma of the gastro-oesophageal junction: a study of the Arbeitsgemeinschaft Internistische Onkologie

P. Galle, V. Kaechele, T. Seufferlein, 2010, Cancer Chemotherapy and Pharmacology.

Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction

F. Bassermann, F. Lordick, Ö. Türeci, 2014, Cancer Immunology, Immunotherapy.

Gemcitabine and oxaliplatin (GEMOX) alone or in combination with cetuximab as first-line treatment for advanced biliary cancer: Final analysis of a randomized phase II trial (BINGO).

J. Pignon, M. Ducreux, T. Greten, 2012 .

Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding study

V. Heinemann, T. Seufferlein, K. Jauch, 2014, Anti-cancer drugs.

Final results of a phase I/II study in patients with pancreatic cancer, malignant melanoma, and colorectal carcinoma with trabedersen.

A. Enk, C. Garbe, T. Seufferlein, 2012 .

Ep‐CAM in malignant liver tumours

P. Ruck, R. Handgretinger, E. Kaiserling, 2000, The Journal of pathology.